Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New...( PRINCETON N.J. July 10 /- Medarex...),Health

PRINCETON, N.J., July 10 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today provided a detailed overview of the company's strategy, strength in research discovery and antibody development, and the multiple opportunities Medarex is engaged in for creating long-term value. In addition, comprehensive updates on current and future antibody programs as well as updated 2008 financial guidance were presented by Medarex's President and CEO, Howard H. Pien, and other members of senior management.

"Medarex's science and technology provides a solid foundation for creating and renewing a broad portfolio of innovative and commercially attractive product candidates," said Mr. Pien. "We remain excited and confident of the path forward for the broad oncology program of ipilimumab, our lead product candidate in development with Bristol-Myers Squibb Company. We are also developing a strong pipeline that includes six other exciting product candidates that represent multiple commercial opportunities for Medarex. We believe that there is tremendous value in our pipeline, and we are well- positioned in our research capabilities and development strategy for sustaining a pipeline of commercially attractive candidates to achieve significant growth in the years ahead."

Product Portfolio

Medarex has developed a portfolio of product candidates that address important disease pathways in oncology and inflammatory diseases, including immune modulation by co-stimulatory and checkpoint molecules, inhibition of pro-inflammatory cytokines, and B-cell targeted approaches. In addition to providing an update on the broad program for ipilimumab, an investigational immunotherapy for multiple oncology indications, Medarex also highlighted the compa
'/>"/>